Daiichi Sankyo Inc. drugs

5 results

  • enhertu - fam - trastuzumab deruxtecan - nxki injection, powder, lyophilized, for solution

    (Fam-Trastuzumab Deruxtecan-Nxki)
    Daiichi Sankyo Inc.
    ENHERTU is indicated for the treatment of adult patients with HER2-positive metastatic breast cancer, HER2-low metastatic breast cancer, HER2-mutant non-small cell lung cancer, advanced HER2-positive gastric cancer, and HER2-positive solid tumors. It is used as monotherapy or in combination, depending on prior treatments and disease progression.
    Medication Details
    Drug Interactions

  • savaysa

    (EDOXABAN TOSYLATE)
    Daiichi Sankyo Inc.
    SAVAYSA is indicated for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for treating deep vein thrombosis and pulmonary embolism after initial therapy with a parenteral anticoagulant. It should not be used in patients with CrCL > 95 mL/min.
    Medication Details
    Drug Interactions

  • vanflyta - quizartinib tablet, film coated

    (Quizartinib)
    Daiichi Sankyo Inc.
    VANFLYTA is indicated for adults with newly diagnosed acute myeloid leukemia (AML) that is FLT3 ITD-positive, used in combination with cytarabine and anthracycline during induction and consolidation phases, and as maintenance therapy after consolidation chemotherapy. It's not approved for maintenance post-allogeneic HSCT.
    Medication Details
    Drug Interactions